NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Accenture ( ACN) was upgraded to Outperform at Wells Fargo. Visibility is improving, and business fundamentals appear to have reached an inflection point.

Archer-Daniels Midland ( ADM) was downgraded to Market Perform at BMO Capital. Valuation call, based on a $36 price target.

Beacon Roofing ( BECN) was downgraded from Outperform to Neutral at Robert Baird. $16 price target. Shingle pricing has turned negative.

ConocoPhillips ( COP) was downgraded to Underweight at Morgan Stanley. Valuation call, based on a $56 price target.

Deere ( DE) was downgraded to Market Perform at Wells Fargo. Company is not likely to raise guidance above current consensus expectations.

Amdocs ( DOX) was started with a Hold rating at ThinkEquity. $30 price target. Future growth will most likely be driven by acquisitions.

Idacorp ( IDA) was upgraded from Hold to Buy at Keybanc. $38.50 price target. Two tax deductions will benefit equity value.

Limited Brands ( LTD) was downgraded to Sell at Goldman Sachs. $24 price target. Company faces earnings headwinds in 2011.

Norfolk Southern ( NSC) was downgraded to Market Perform at Wells Fargo. Valuation call, as coal demand could wane.

Rubicon Technology ( RBCN) was initiated with a Sell rating at Merriman, Curhan Ford. Supply has caught up to demand in LCD lighting.

The Hanover Insurance Group ( THG) was downgraded to Equal Weight from Overweight at Barclays. Less earnings power and reduced ROE improvement, Barclays said. Price target cut to $46 from $49.

Walgreen ( WAG) was upgraded from Equal-Weight to Overweight at Morgan Stanley. $40 price target. Company faces easy comparisons for the flu season.

Wright Medical ( WMGI) was downgraded from Outperform to Neutral at Robert Baird. $17 price target. Company could struggle to achieve consensus earnings expectations.

Xilinx ( XLNX) was downgraded from Neutral to Sell at Goldman Sachs. Estimates were also cut, as cyclical pressures could hurt earnings. $22 price target.

STOCK COMMENTS / EPS CHANGES

Accenture 2011 and 2012 estimates boosted to $3.03 and $3.46, respectively, at Credit Suisse. Banking on enterprise spend recovery, Credit Suisse said. Maintain Outperform rating and $55 price target.

Accenture estimates, target increased at Citigroup. Estimates were raised through 2012. Company had a good quarter and boosted guidance. Buy rating and new $53 price target.

Altera ( ALTR) estimates, target reduced at Goldman. Estimates were cut through 2012, Goldman Sachs said. Company faces cyclical headwinds. Neutral rating and new $26 price target.

Covance ( CVD) estimates, target boosted at Jefferies. Shares now seen reaching $54, according to Jefferies. Estimates also upped, given the new $2.2 billion contract from SNY. Buy rating.

If you liked this article you might like

Nvidia Inspires Chipmaker Gains but Rest of Tech Gets Left Behind

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

CEO of Accenture North America: We Are Committed to Gender Parity by 2025

Accenture CEO: Consulting is About Reskilling for Digital, Cloud and Security

Why Apple's Partnership With Accenture Is a Big Deal